CN / EN

Home >  News Center >  “The First Brain Health Stock” Has Listed Successfully in the US

“The First Brain Health Stock” Has Listed Successfully in the US

On March 8, 2021 EDT, Zhongyuan Biotech was officially approved by the U.S. Financial Regulatory Authority (FINRA) to go public, and the stock will trade under the ticker symbol: ZHYBF. This is a major milestone on the way to listing on NASDAQ, and it will be officially traded one week later.

 

Move Forward

As the global epidemic continues, Zhongyuan Biotech has always been focused on the research and development of new drugs for neurological diseases. It has made breakthroughs in the research and development of new drugs to overcome cognitive impairment in Alzheimer's disease and white matter injury (Leukoencephalopathy). The relevant research results passed the priority examination of the State Patent Office, obtained the national invention patent within 2 months, and completed the China clinical trial registration (registration number: ChiCTR2000041229). The progress and achievements of the Group's research and development have attracted great attention in the industry, and the druggable experiment results are even more exciting for industry insiders. Zhongyuan Biotech's innovative new botanical drugs and small molecule chemical drugs have both started preclinical IND application and are expected to complete approval and enter clinical phase I trial soon. With the support and help of the whole society and industrial partners, Zhongyuan Biotech will continue to forge ahead and bring new nervous system drugs to the market to benefit patients with brain diseases and their families all over the world as soon as possible!

 

Milestone

As the successful listing of NASDAQ, we will see into a broader room for growth for Zhongyuan Biotech. For now, we've cooperated with several securities traders and investment institutions who have rich experience in capital market operation. After the opening of the company's stock will present the expected performance of steady growth, we also firmly believe that more and more partners will be with us all the way to share the joy and fruits of the harvest.



Last:BF co-builds “Key Laboratory of Genetic Metabolism Research” Return Next:Zhongyuan Biotech Accesses The US Capital Market